Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0UM4S
|
|||
Former ID |
DIB010842
|
|||
Drug Name |
ASG-15ME
|
|||
Drug Type |
Antibody
|
|||
Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1 | [1] | |
Urothelial carcinoma [ICD-11: 2C92.0] | Phase 1 | [2] | ||
Company |
Agensys; seattle genetics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | SLIT and NTRK-like family member 6 (SLITRK6) | Target Info | . | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01963052) ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of Seattle Genetics. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.